Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cindy Cheng

Internal Medicine Tewksbury, MA Medical Doctor

NPI 1114989613 CMS profile 95628

600 Clark Rd, Ste 200, Tewksbury, MA 01876

Open in the dashboard

General payments

$6,558

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cindy Cheng of Tewksbury, MA is reported in the CMS Open Payments database as having received $6,558 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,375 14
2024 General $755 8
2023 General $591 6
2022 General $172 3
2021 General $795 18
2020 General $548 15
2019 General $2,322 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cindy Cheng
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Cindy Cheng were reported at $1,375. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Cindy Cheng Internal Medicine median Middle half National median
2019 $2,322 $159 $48–$570 $163
2020 $548 $119 $33–$402 $114
2021 $795 $135 $37–$521 $132
2022 $172 $141 $42–$496 $149
2023 $591 $149 $45–$519 $160
2024 $755 $154 $47–$537 $164
2025 $1,375 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,598 26 payments
  2. GlaxoSmithKline, LLC. $1,347 29 payments
  3. Pfizer Inc. $460 20 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $425 4 payments
  5. ITI, Inc. $415 4 payments
  6. AbbVie, Inc. $344 4 payments
  7. Teva Pharmaceuticals USA, Inc. $259 5 payments
  8. Novartis Pharmaceuticals Corporation $234 11 payments
  9. Janssen Pharmaceuticals, Inc $229 12 payments
  10. Allergan Inc. $219 6 payments
  11. Other $1,027 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,528 161 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. BREZTRI $716 8 payments
  2. TRELEGY ELLIPTA $529 13 payments
  3. AIRSUPRA $435 4 payments
  4. Kerendia $425 4 payments
  5. NUCALA $363 3 payments
  6. VRAYLAR $326 3 payments
  7. CAPLYTA $301 3 payments
  8. FARXIGA $289 5 payments
  9. ENTRESTO $234 11 payments
  10. ELIQUIS $232 7 payments
  11. Other $3,694 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 112 drugs

Part D claims

6,678

Median for Family Practice: 1,826

Drug cost

$652,518

Median for Family Practice: $120,094

Branded share of claims

23%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 108 $128,459
Eliquis Apixaban Brand 108 $91,627
Farxiga Dapagliflozin Propanediol Brand 58 $62,335
Januvia Sitagliptin Phosphate Brand 42 $60,824
Ozempic Semaglutide Brand 45 $40,500
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 63 $38,819
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 38 $29,981
Trulicity Dulaglutide Brand 25 $26,787
Xarelto Rivaroxaban Brand 17 $26,412
Oxycontin Oxycodone Hcl Brand 11 $24,362

The 10 drugs with the highest cost, of 112 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$67,415

Of which drugs: $7,516

Medicare patients

222

Average age 72

Services billed

1,271

190 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Chronic kidney disease 37%
Diabetes 31%
Depression 23%
Osteoporosis 21%
Ischemic heart disease 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 15 15 $4,344
Vaccine for influenza for injection into muscle 90653 Office 30 30 $2,455

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $304
$304 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $136
$136 — —
AREXVY
  • GlaxoSmithKline, LLC. $125
$125 — —
VRAYLAR
  • AbbVie, Inc. $121
$121 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $41
$41 58 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record